Clinical Trial Finder

« Return to Results

View on ClinicalTrials.gov Export CSV

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Program Status

Recruiting

Phase

Phase 1 Phase 2

Prior Immunotherapy Allowed

Yes

CRC-directed Trial

Yes

Drugs

BMS-936558-01, BMS-986340

Tags

MSI-H/ MMRd, MSS/ MMRp

Comments

BMS-986340 (anti-CCR8 monoclonal antibody) monotherapy and later in combination with nivolumab (anti PD-1, immunotherapy)

Helpful Links

Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models

Location	Location Status
United States
Community Cancer Institute Clovis, California 93611	Recruiting
USC/Norris Comprehensive Cancer Center Los Angeles, California 90033	Recruiting
Hoag Memorial Hospital Presbyterian Newport Beach, California 92663	Recruiting
University of Iowa Iowa City, Iowa 52242	Recruiting
John Theurer Cancer Center Hackensack, New Jersey 07601	Recruiting
Local Institution - 0006 New York, New York 10032	Active, not recruiting
Local Institution - 0002 New York, New York 10065	Completed
Providence Cancer Center Oncology and Hematology Care- Eastside Portland, Oregon 97213	Recruiting
Local Institution - 0063 Nashville, Tennessee 37067	Not yet recruiting
Vanderbilt University Medical Center Nashville, Tennessee 37232	Recruiting
Houston Methodist Hospital Houston, Texas 77030	Recruiting
Australia
Blacktown Hospital Blacktown, New South Wales 2148	Recruiting
Liverpool Hospital Liverpool, New South Wales 2170	Recruiting
Princess Alexandra Hospital Brisbane, Queensland 4102	Recruiting
Cabrini Hospital - Malvern Malvern, Victoria 3144	Recruiting
St Vincent's Hospital Melbourne, Victoria 3065	Recruiting
One Clinical Research Nedlands, Western Australia 6009	Recruiting
Canada
Cross Cancer Institute Edmonton, Alberta T6X 1E8	Recruiting
BC Cancer Vancouver Vancouver, British Columbia V5Z 4E6	Recruiting
Hamilton Health Sciences-Juravinski Cancer Centre Hamilton, Ontario L8V5C2	Recruiting
Local Institution - 0009 Toronto, Ontario M5G 2M9	Completed
Centre Hospitalier de luniversite de Montreal Montreal, Quebec H2X 0A9	Recruiting
The Ottawa Hospital Cancer Centre Ottawa K1H 8L6	Recruiting
China
Local Institution - 0067 Beijing, Beijing Municipality 100142	Not yet recruiting
Local Institution - 0066 Jinan, Shandong 250117	Not yet recruiting
Local Institution - 0065 Hangzhou, Zhejiang 310022	Not yet recruiting
Germany
Universitaetsklinikum Ulm Ulm, Baden-Wurttemberg 89081	Recruiting
Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit Dresden 01307	Recruiting
Universitaetsklinikum Essen Essen 45147	Recruiting
Universitatsklinikum Frankfurt Frankfurt 60590	Recruiting
Universitaetsklinikum Wuerzburg Würzburg 97078	Recruiting
Israel
Rabin Medical Center Petah Tikva, Central District 4941492	Recruiting
Local Institution - 0035 Ramat Gan, Central District 5265601	Withdrawn
Sheba Medical Center Ramat Gan, Central District 5265601	Recruiting
Rambam Health Care Campus Haifa, Northern District 3109601	Recruiting
Sourasky Medical Center Tel Aviv, Tell Abīb 6423906	Recruiting
Italy
Humanitas Rozzano, Milano 20089	Recruiting
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia Candiolo, Torino 10060	Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 Milan 20133	Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli 80131	Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Roma 00168	Recruiting
ospedale le scotte-U.O.C. Immunoterapia Oncologica Siena 53100	Recruiting
Japan
National Cancer Center Hospital East Kashiwa, Chiba 277-8577	Recruiting
Spain
Hospital Universitario Virgen de la Victoria Málaga, Andalusia 29010	Recruiting
Institut Catalan d Oncologia (ICO) - Badalona Badalona, Barcelona [Barcelona] 08916	Recruiting
Hospital Universitari Vall d'Hebron Barcelona, Barcelona [Barcelona] 08035	Recruiting
Hospital Universitario 12 de Octubre Madrid, Madrid, Comunidad de 28041	Recruiting
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD Madrid 28040	Recruiting
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid-CIOCC Madrid 28050	Recruiting
Clinica Universidad de Navarra-oNCOLOGY Pamplona 31008	Recruiting

Contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
855-907-3286 Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.
CONTACT

Inclusion Criteria

* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
* Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* Radiographically documented progressive disease on or after the most recent therapy.
* Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.

Exclusion Criteria

* Women who are pregnant or breastfeeding.
* Primary central nervous system (CNS) malignancy.
* Untreated CNS metastases.
* Leptomeningeal metastases.
* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.
* Active, known, or suspected autoimmune disease.
* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.
* Prior organ or tissue allograft.
* Uncontrolled or significant cardiovascular disease.
* Major surgery within 4 weeks of study drug administration.
* History of or with active interstitial lung disease or pulmonary fibrosis.

Other protocol-defined inclusion/exclusion criteria apply

NCT ID

NCT04895709

Date Trial Added

2021-05-20

Updated Date

2025-09-25